1. Home
  2. ADUS vs IMNM Comparison

ADUS vs IMNM Comparison

Compare ADUS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Addus HomeCare Corporation

ADUS

Addus HomeCare Corporation

HOLD

Current Price

$117.59

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$26.42

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADUS
IMNM
Founded
1979
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.5B
IPO Year
2009
2020

Fundamental Metrics

Financial Performance
Metric
ADUS
IMNM
Price
$117.59
$26.42
Analyst Decision
Buy
Strong Buy
Analyst Count
9
10
Target Price
$133.78
$32.80
AVG Volume (30 Days)
211.9K
991.6K
Earning Date
05-04-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
23.40
51.40
EPS
2.85
N/A
Revenue
N/A
$6,941,000.00
Revenue This Year
$9.17
N/A
Revenue Next Year
$4.70
$1,127.34
P/E Ratio
$41.42
N/A
Revenue Growth
N/A
N/A
52 Week Low
$87.95
$8.67
52 Week High
$124.44
$28.04

Technical Indicators

Market Signals
Indicator
ADUS
IMNM
Relative Strength Index (RSI) 58.70 64.01
Support Level $106.22 $19.28
Resistance Level $120.27 $27.14
Average True Range (ATR) 3.57 1.42
MACD -0.53 0.30
Stochastic Oscillator 69.79 67.08

Price Performance

Historical Comparison
ADUS
IMNM

About ADUS Addus HomeCare Corporation

Addus HomeCare Corp is engaged in the provision of in-home care services. The Company has three reportable segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, mainly to the elderly, chronically ill, and disabled individuals. The Hospice segment provides physical, emotional, and spiritual care for terminally ill patients and their families. The Home Health segment provides medical services to individuals requiring care during illness or recovery. It generates the majority of its revenue from the Personal Care segment.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: